Oliver Distler
#121,859
Most Influential Person Now
Researcher
Oliver Distler's AcademicInfluence.com Rankings
Oliver Distlercomputer-science Degrees
Computer Science
#4954
World Rank
#5233
Historical Rank
Machine Learning
#1141
World Rank
#1161
Historical Rank
Artificial Intelligence
#1372
World Rank
#1400
Historical Rank
Database
#2123
World Rank
#2233
Historical Rank
Download Badge
Computer Science
Why Is Oliver Distler Influential?
(Suggest an Edit or Addition)Oliver Distler's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. (2013) (2731)
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative (2013) (1713)
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database (2010) (1000)
- Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. (2019) (727)
- Update of EULAR recommendations for the treatment of systemic sclerosis (2015) (712)
- Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis (2012) (681)
- Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study (2013) (604)
- Synovial fibroblasts: key players in rheumatoid arthritis. (2006) (588)
- Anti–Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis (2002) (529)
- MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. (2010) (492)
- Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model (2017) (434)
- Angiogenic and angiostatic factors in the molecular control of angiogenesis. (2003) (432)
- Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. (2007) (381)
- Systemic sclerosis (2021) (356)
- Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group (2014) (355)
- Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group (2010) (344)
- Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. (2013) (335)
- Mapping and predicting mortality from systemic sclerosis (2017) (328)
- Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis (2004) (314)
- Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. (2002) (310)
- The Potential of Adiponectin in Driving Arthritis1 (2006) (296)
- Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers (2002) (281)
- HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia (2001) (267)
- Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis (2017) (264)
- The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. (2005) (263)
- Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. (2005) (254)
- Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database (2012) (251)
- Autophagy regulates TNFα-mediated joint destruction in experimental arthritis (2012) (242)
- Overview of pathogenesis of systemic sclerosis. (2006) (238)
- Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis (2015) (237)
- Platelet-derived serotonin links vascular disease and tissue fibrosis (2011) (233)
- Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts (2007) (220)
- Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis (2009) (214)
- Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. (2007) (213)
- Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis (2017) (206)
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. (2020) (205)
- Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. (2009) (198)
- Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells (2017) (196)
- Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis (2008) (187)
- Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. (2013) (185)
- β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis (2012) (184)
- Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. (2004) (184)
- Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. (2007) (178)
- Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study (2012) (175)
- Microparticles as mediators of cellular cross-talk in inflammatory disease (2006) (173)
- Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis (2013) (169)
- Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. (2001) (166)
- The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis (2013) (165)
- How does endothelial cell injury start? The role of endothelin in systemic sclerosis (2007) (163)
- Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. (2020) (158)
- Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis (2015) (155)
- Role of MicroRNAs in Fibrosis (2012) (154)
- Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. (2007) (153)
- Animal models of systemic sclerosis: prospects and limitations. (2010) (152)
- The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy (2009) (150)
- Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis (2007) (150)
- The release of microparticles by apoptotic cells and their effects on macrophages (2005) (145)
- The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements (2020) (142)
- Brief Report: Pulmonary Function Tests: High Rate of False‐Negative Results in the Early Detection and Screening of Scleroderma‐Related Interstitial Lung Disease (2015) (136)
- Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study (2016) (136)
- Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. (2005) (135)
- Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. (2012) (133)
- Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial (2020) (132)
- Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study (2019) (130)
- Vitamin D receptor regulates TGF-β signalling in systemic sclerosis. (2015) (120)
- The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review. (2017) (120)
- Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis (2017) (120)
- Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. (2008) (119)
- Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study (2016) (119)
- Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study (2016) (119)
- Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. (2011) (116)
- Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. (2004) (115)
- Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis (2011) (115)
- Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. (2008) (114)
- An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. (2016) (113)
- Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis (2014) (113)
- JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. (2012) (110)
- The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index (2016) (106)
- Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis (2009) (106)
- Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. (2009) (105)
- Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials (2013) (104)
- The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. (2009) (104)
- Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis (2009) (103)
- COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD (2020) (101)
- Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling (2014) (100)
- Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. (2015) (99)
- Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis (2013) (99)
- The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. (2008) (97)
- Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) (2017) (97)
- The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. (2010) (96)
- Angiogenesis and vasculogenesis in systemic sclerosis. (2006) (95)
- EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells (2008) (94)
- Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. (2006) (94)
- Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis (2012) (92)
- Systemic sclerosis: state of the art on clinical practice guidelines (2018) (91)
- Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database (2020) (90)
- SPI1/PU.1 controls fibroblast polarization and tissue fibrosis (2019) (90)
- The controversial role of tumor necrosis factor alpha in fibrotic diseases. (2008) (90)
- Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis (2012) (89)
- The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. (2005) (89)
- Mechanisms of vascular damage in SSc--implications for vascular treatment strategies. (2008) (89)
- Transforming growth factor-&bgr;-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis (2016) (89)
- Predictors of progression in systemic sclerosis patients with interstitial lung disease (2020) (87)
- Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. (2012) (87)
- Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. (1999) (87)
- Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway (2011) (86)
- Cardiac arrhythmias and conduction defects in systemic sclerosis. (2014) (86)
- A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study (2014) (84)
- Linking angiogenesis to bone destruction in arthritis. (2005) (83)
- Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. (2007) (82)
- Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis (2013) (82)
- Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis (2014) (82)
- Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening (2017) (82)
- Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis (2013) (81)
- Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model (2018) (80)
- Mechanisms of vascular damage in systemic sclerosis (2009) (80)
- Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling (2012) (80)
- Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study (2014) (79)
- Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case–control study (2007) (79)
- Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis (2012) (78)
- Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy (2015) (77)
- Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. (2016) (77)
- Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. (2015) (76)
- Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group (2018) (76)
- Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis (2012) (75)
- Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. (2019) (75)
- Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. (2021) (75)
- Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. (2009) (75)
- Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. (2011) (75)
- Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis (2018) (74)
- Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs) (2020) (74)
- The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis (2018) (73)
- Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias (2015) (73)
- Physiologically low oxygen concentrations determined in fetal skin regulate hypoxia‐inducible factor 1 and transforming growth factor β3 (2002) (72)
- Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis (2015) (70)
- SAT0296 FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN (2019) (70)
- Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. (2010) (70)
- Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). (2016) (70)
- THE MOLECULAR CONTROL OF ANGIOGENESIS (2002) (70)
- Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies (2009) (69)
- Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases. (2018) (68)
- Olive Leaf Extract Attenuates Inflammatory Activation and DNA Damage in Human Arterial Endothelial Cells (2019) (67)
- Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. (2005) (65)
- IL-15 and its role in rheumatoid arthritis (2003) (63)
- Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis (2016) (63)
- Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis (2020) (63)
- The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis (2011) (63)
- Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries (2011) (62)
- Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. (2014) (62)
- Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study (2014) (61)
- The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (2016) (60)
- Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis (2015) (60)
- Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise (2012) (60)
- Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group (2018) (60)
- Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort (2019) (60)
- Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis (2019) (59)
- Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. (2008) (58)
- Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition (2017) (58)
- Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis (2018) (58)
- Nucleofection: a new, highly efficient transfection method for primary human keratinocytes * (2005) (57)
- HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men. (2000) (57)
- Hypoxia in the pathogenesis of systemic sclerosis (2009) (57)
- Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database (2015) (56)
- Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies (2015) (56)
- The role of membrane lipids in the induction of macrophage apoptosis by microparticles (2007) (56)
- Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. (2018) (56)
- Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. (2020) (56)
- Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. (2011) (55)
- Pharyngeal swallowing and oesophageal motility during a solid meal test: a prospective study in healthy volunteers and patients with major motility disorders. (2017) (55)
- Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. (2011) (55)
- Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis (2016) (55)
- Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression (2014) (54)
- Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. (2008) (54)
- Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. (2003) (53)
- Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis (2012) (52)
- S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis (2014) (52)
- Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. (2012) (52)
- Emerging strategies for treatment of systemic sclerosis (2016) (51)
- WNT3a and WNT5a Transported by Exosomes Activate WNT Signaling Pathways in Human Cardiac Fibroblasts (2019) (51)
- Imatinib as a novel therapeutic approach for fibrotic disorders. (2008) (51)
- Innovative antifibrotic therapies in systemic sclerosis (2012) (50)
- The Fra-2 transgenic mouse model of systemic sclerosis. (2013) (50)
- Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management (2020) (50)
- Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group (2012) (49)
- Effects of rituximab in connective tissue disorders related interstitial lung disease. (2016) (49)
- Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial (2020) (48)
- Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials (2011) (48)
- Microparticles stimulate angiogenesis by inducing ELR+ CXC-chemokines in synovial fibroblasts (2010) (48)
- COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension (2021) (47)
- Profile of gastrointestinal involvement in patients with systemic sclerosis (2012) (47)
- Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis (2018) (46)
- Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. (2008) (46)
- Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study (2014) (45)
- Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension (2019) (45)
- Non organ based laboratory markers in systemic sclerosis. (2003) (45)
- Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort (2020) (44)
- Induction of apoptosis in circulating angiogenic cells by microparticles. (2011) (44)
- Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study (2018) (44)
- Endothelial progenitor cells: novel players in the pathogenesis of rheumatic diseases. (2009) (43)
- Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis (2013) (42)
- Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled Trial (2019) (42)
- Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS) (2009) (42)
- Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis (1999) (42)
- Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (2017) (41)
- Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. (2001) (41)
- Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group (2010) (41)
- The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis (2017) (40)
- Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? (2010) (40)
- Discrepancy between mRNA and protein expression of tumour suppressor maspin in synovial tissue may contribute to synovial hyperplasia in rheumatoid arthritis (2004) (40)
- TGFβ-induced epigenetic deregulation of SOCS3 facilitates STAT3-signaling to promote fibrosis. (2020) (40)
- Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease–Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities (2019) (40)
- Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease—insights and potential therapeutic implications (2007) (39)
- The AP1 Transcription Factor Fosl2 Promotes Systemic Autoimmunity and Inflammation by Repressing Treg Development. (2020) (38)
- Activation of the IL-4 STAT Pathway in Rheumatoid Synovium1 (2000) (38)
- Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group (2010) (38)
- Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. (2019) (37)
- Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment. (2006) (36)
- The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (2016) (36)
- Cardiomyopathy in Murine Models of Systemic Sclerosis (2015) (36)
- Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis. (2017) (36)
- The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis (2012) (35)
- Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. (2009) (35)
- RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. (2017) (35)
- Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages (2014) (34)
- Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis (2014) (34)
- Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis (2018) (34)
- JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment (2017) (34)
- Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. (2019) (33)
- Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. (2015) (33)
- ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis (2020) (33)
- Haematopoietic stem cell transplantation in systemic sclerosis (2018) (33)
- Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices (2011) (33)
- Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis (2019) (33)
- Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial (2020) (32)
- Inflammation: Microparticles and their roles in inflammatory arthritides (2010) (32)
- Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials (2020) (32)
- The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc (2016) (32)
- Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis (2019) (32)
- Long noncoding RNA H19X is a key mediator of TGFβ driven fibrosis. (2020) (31)
- Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability (2014) (31)
- Toll-like receptors in rheumatoid arthritis joint destruction mediated by two distinct pathways (2004) (31)
- Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features (2019) (31)
- Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection. (2007) (31)
- Tribbles homologue 3 stimulates canonical TGF-β signalling to regulate fibroblast activation and tissue fibrosis (2015) (31)
- Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis – a randomized controlled, cross‐over trial (2007) (31)
- Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease (2019) (31)
- Systemic sclerosis in 2014: Advances in cohort enrichment shape future of trial design (2015) (30)
- Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. (2010) (30)
- Outcome Measures for Clinical Trials in Interstitial Lung Diseases. (2015) (30)
- Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. (2010) (30)
- Inhibition of sumoylation prevents experimental fibrosis (2012) (29)
- Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1 (2012) (29)
- Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis (2016) (29)
- Pomalidomide is effective for prevention and treatment of experimental skin fibrosis (2012) (28)
- Hyperlipidemia and inhibitors of HIV protease (2001) (28)
- Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. (2012) (28)
- Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators (2018) (28)
- Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. (2020) (28)
- Use of biologics and other novel therapies for the treatment of systemic sclerosis (2017) (28)
- Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? (2011) (28)
- Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). (2000) (27)
- Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling (2013) (27)
- Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population (2015) (27)
- Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study (2019) (26)
- EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research (2011) (26)
- 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study (2021) (26)
- The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease (2020) (26)
- Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure (2019) (25)
- Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study) (2019) (25)
- A novel ultra-light suction device for mechanical characterization of skin (2018) (25)
- Tie2 as a novel key factor of microangiopathy in systemic sclerosis (2015) (25)
- Clinical trial design in scleroderma: where are we and where do we go next? (2012) (25)
- Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease (2011) (25)
- Muscle involvement in systemic sclerosis: points to consider in clinical trials (2017) (24)
- International Classification of Functioning, Disability and Health Core Set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative. (2012) (24)
- Activating transcription factor 3 regulates canonical TGFβ signalling in systemic sclerosis (2015) (24)
- Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides (2019) (24)
- Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry (2021) (24)
- Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II) (2019) (24)
- Activation of pregnane X receptor inhibits experimental dermal fibrosis (2013) (24)
- Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. (2012) (24)
- Differential Adherence of Osteoarthritis and Rheumatoid Arthritis Synovial Fibroblasts to Cartilage and Bone Matrix Proteins and its Implication for Osteoarthritis Pathogenesis (2004) (24)
- Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort (2020) (23)
- Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. (2004) (23)
- Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. (2006) (23)
- The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. (2020) (23)
- 18F-AzaFol for Detection of Folate Receptor-β Positive Macrophages in Experimental Interstitial Lung Disease—A Proof-of-Concept Study (2019) (22)
- Location-specific mechanical response and morphology of facial soft tissues. (2018) (22)
- The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. (2021) (22)
- Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement (2004) (22)
- Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial (2022) (21)
- Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS) (2021) (21)
- Double-blind, Randomized, 8-week Placebo-controlled followed by a 16-week open label extension study, with the LPA1 receptor antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis (2018) (21)
- Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2 (2018) (21)
- Analysis of gene expression patterns in systemic sclerosis fibroblasts using RNA arbitrarily primed-polymerase chain reaction for differential display. (2007) (21)
- The epigenetic architecture at gene promoters determines cell type-specific LPS tolerance. (2017) (21)
- Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. (2020) (20)
- Personalized Medicine in Systemic Sclerosis: Facts and Promises (2014) (20)
- The impact of slice-reduced computed tomography on histogram-based densitometry assessment of lung fibrosis in patients with systemic sclerosis. (2018) (20)
- [Rheumatoid arthritis: new developments in the pathogenesis with special reference to synovial fibroblasts]. (2001) (20)
- Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors (2013) (20)
- Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis (2018) (20)
- Stiff skin syndrome: evidence for an inflammation-independent fibrosis? (2009) (20)
- Treatment of pulmonary arterial hypertension(PAH) (2010) (19)
- Novel treatment approaches to fibrosis in scleroderma. (2008) (19)
- Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry (2020) (19)
- Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers. (2010) (19)
- The emerging application of semi-quantitative and quantitative capillaroscopy in systemic sclerosis. (2018) (19)
- OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic Sclerosis (2019) (19)
- Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis (2022) (19)
- Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort (2017) (18)
- Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. (2020) (18)
- European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis (2018) (18)
- International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis (2012) (18)
- Identification and Isolation of Cardiac Fibroblasts From the Adult Mouse Heart Using Two-Color Flow Cytometry (2019) (17)
- 18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis (2018) (17)
- Criteria to select molecular targets for anti-fibrotic therapy. (2008) (17)
- Safety and efficacy of extracorporeal shock wave therapy (ESWT) in calcinosis cutis associated with systemic sclerosis. (2016) (17)
- Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. (2009) (17)
- Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis (2018) (17)
- No Evidence for a Decrease in Physical Activity Among Swiss Office Workers During COVID-19: A Longitudinal Study (2021) (17)
- Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis (2013) (17)
- Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect? (2007) (16)
- Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis (2020) (16)
- Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. (2015) (16)
- Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study. (2019) (16)
- Chromatin accessibility landscapes of skin cells in systemic sclerosis nominate dendritic cells in disease pathogenesis (2020) (16)
- Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study (2019) (16)
- What have multicentre registries across the world taught us about the disease features of systemic sclerosis? (2017) (16)
- No evidence for an effect of working from home on neck pain and neck disability among Swiss office workers: Short-term impact of COVID-19 (2021) (16)
- Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise? (2013) (16)
- COVID-19 vaccination in autoimmune disease (COVAD) survey protocol (2021) (16)
- Treatment of systemic sclerosis: is there any hope for the future? (2016) (16)
- The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor β and Contributes to the Development of Experimental Dermal Fibrosis (2014) (15)
- Tocilizumab for systemic sclerosis: implications for future trials (2016) (15)
- Heart non-specific effector CD4+ T cells protect from postinflammatory fibrosis and cardiac dysfunction in experimental autoimmune myocarditis (2019) (15)
- Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study (2018) (15)
- Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. (2020) (15)
- Molecular targets for therapy in systemic sclerosis (2012) (15)
- Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease (2020) (15)
- Might Nailfold Capillaroscopy Be a “Proxy” for Lung Involvement in Connective Tissue Diseases? (2019) (14)
- [Molecular and cellular basis of joint destruction in rheumatoid arthritis]. (2006) (14)
- Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse (2020) (14)
- Use of methotrexate in patients with scleroderma and mixed connective tissue disease. (2010) (14)
- Is There Evidence for Vasculitis in Systemic Sclerosis? (2012) (14)
- Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement. (2019) (14)
- Technology Insight: gene transfer and the design of novel treatments for rheumatoid arthritis (2006) (13)
- Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database (2018) (13)
- Antisense strategies in degenerative joint diseases: sense or nonsense? (2006) (13)
- [Treatment of pulmonary arterial hypertension (PAH): recommendations of the Cologne Consensus Conference 2010]. (2010) (13)
- [Vascular changes in the pathogenesis of systemic sclerosis]. (2004) (13)
- Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. (2018) (13)
- Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database (2020) (13)
- Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database (2020) (13)
- The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease? (2020) (13)
- Emerging targeted therapies in scleroderma lung and skin fibrosis. (2011) (13)
- TET1 is an important transcriptional activator of TNFα expression in macrophages (2019) (13)
- Microparticles and Kawasaki disease: a marker of vascular damage? (2011) (12)
- Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. (2020) (12)
- Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis (2020) (12)
- COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic (2020) (12)
- OP0245 PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC (2019) (12)
- Experimental Mouse Model of Bleomycin‐Induced Skin Fibrosis (2019) (12)
- Novel Aspects in the Pathophysiology of Peripheral Vasculopathy in Systemic Sclerosis. (2013) (12)
- Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis (2021) (12)
- Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. (2014) (12)
- Pulmonary hypertension in patients with chronic obstructive lung disease: results from COMPERA. (2021) (12)
- Detect-and-Segment: a Deep Learning Approach to Automate Wound Image Segmentation (2021) (11)
- Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability (2020) (11)
- SAR100842, an Antagonist of Lysophaphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study. (2014) (11)
- Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. (2010) (11)
- Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors (2018) (11)
- Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo (2008) (11)
- Primary structure of the V3 region of gp120 from sequential human immunodeficiency virus type 1 isolates obtained from patients from the time of seroconversion. (1995) (11)
- Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database (2012) (11)
- Characterization of the V3 region of HIV-1 isolates from Sydney, Australia. (1995) (11)
- Serum Biomarkers for Connective Tissue and Basement Membrane Remodeling Are Associated with Vertebral Endplate Bone Marrow Lesions as Seen on MRI (Modic Changes) (2020) (11)
- Doppler ultrasound identifies increased resistive indices in SSc (2003) (11)
- Abnormal esophageal motility during a solid test meal in systemic sclerosis—detection even in very early disease and association with disease progression (2018) (10)
- Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis (2022) (10)
- Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score (2021) (10)
- Absenteeism and presenteeism in healthcare workers due to respiratory illness (2020) (10)
- Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis (2017) (10)
- Nodular Regenerative Hyperplasia of the Liver: A Rare Vascular Complication in Systemic Sclerosis (2018) (10)
- Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed (2011) (10)
- Elevated Fibronectin Levels in Profibrotic CD14+ Monocytes and CD14+ Macrophages in Systemic Sclerosis (2021) (10)
- Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Reply. (2019) (10)
- On-site multi-component intervention to improve productivity and reduce the economic and personal burden of neck pain in Swiss office-workers (NEXpro): protocol for a cluster-randomized controlled trial (2020) (9)
- OP0034 The Serotonin Receptor 2 Inhibitor Terguride Has Beneficial Effects on Skin Fibrosis: Results from A Phase 2 Proof of Concept Study (2016) (9)
- Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA‐125b in Systemic Sclerosis (2019) (9)
- Activated Cardiac Fibroblasts Control Contraction of Human Fibrotic Cardiac Microtissues by a β-Adrenoreceptor-Dependent Mechanism (2020) (8)
- The AP-1 Transcription Factor Fosl-2 Regulates Autophagy in Cardiac Fibroblasts during Myocardial Fibrogenesis (2021) (8)
- Evidence-based consensus recommendations for the identification and management of interstitial lung disease in systemic sclerosis (2019) (8)
- Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey (2019) (8)
- Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study (2019) (8)
- On the Reliability of Suction Measurements for Skin Characterization. (2020) (8)
- Potential of Photon-Counting Detector CT for Radiation Dose Reduction for the Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis (2022) (8)
- OP0275 Nailfold Videocapillaroscopy and Other Predictive Factors Associated with New Digital Ulcers in Systemic Sclerosis: Data from the Cap Study (2013) (8)
- Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual (2019) (8)
- Evaluation of botulinum toxin A injections for the treatment of refractory chronic digital ulcers in patients with systemic sclerosis. (2020) (8)
- OP0289 A Prospective, Randomized, Open-Label, Assessor-Blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids versus Glucocorticoids Alone in Patients with Polymyositis and Dermatomyositis (Prometheus Trial) (2014) (8)
- Subtractive hybridization. (2007) (8)
- [Targeted therapy of pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016]. (2016) (7)
- Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study (2022) (7)
- Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. (2019) (7)
- Wound Image Quality From a Mobile Health Tool for Home-Based Chronic Wound Management With Real-Time Quality Feedback: Randomized Feasibility Study (2021) (7)
- Vascular Disease in Systemic Sclerosis (2010) (7)
- Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study (2021) (7)
- Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation (2021) (7)
- Personal factors in systemic sclerosis and their coverage by patient-reported outcome measures. A multicentre European qualitative study and literature review. (2015) (7)
- Distinct expression of adhesion molecules on skin fibroblasts from patients with diffuse and limited systemic sclerosis. A pilot study. (2005) (7)
- Patients with systemic sclerosis show phenotypic and functional defects in neutrophils (2021) (7)
- OP0035 Preliminary analysis of nailfold capillaroscopy in the very early diagnosis of systemic sclerosis (VEDOSS): the capi-vedoss experience (2017) (7)
- Points to consider when doing a trial primarily involving the heart (2017) (7)
- Recent progress and missing gaps to achieve goal in the care of systemic sclerosis–associated interstitial lung disease (2020) (7)
- Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review (2021) (7)
- Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis (2021) (6)
- Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis (2021) (6)
- OP0064 EVIDENCE-BASED CONSENSUS RECOMMENDATIONS FOR THE IDENTIFICATION AND MANAGEMENT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS (2019) (6)
- Frontiers of antifibrotic therapy in systemic sclerosis (2018) (6)
- Increased expression of the TNF superfamily member LIGHT/TNFSF14 and its receptors (HVEM and LTßR) in patients with systemic sclerosis (2018) (6)
- An Optimized Tissue Dissociation Protocol for Single-Cell RNA Sequencing Analysis of Fresh and Cultured Human Skin Biopsies (2022) (6)
- Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial (2022) (6)
- Patient and healthcare professional eHealth literacy and needs for systemic sclerosis support: a mixed methods study (2021) (6)
- Visual problem and low back pain as initial manifestation of multiple myeloma complicating pre-existing systemic sclerosis. (2014) (6)
- Skin lesions in anti-Pm-Scl-70 positive systemic sclerosis-dermatomyositis overlap syndrome improve during local PUVA phototherapy. (2013) (6)
- Staphylococcus aureus impairs dermal fibroblast functions with deleterious effects on wound healing (2021) (6)
- Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial (2021) (6)
- OP0065 THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS (VEDOSS) PROJECT: PREDICTORS TO DEVELOP DEFINITE DISEASE FROM AN INTERNATIONAL MULTICENTRE STUDY (2019) (6)
- Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients With Systemic Sclerosis. (2019) (6)
- Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. (2021) (6)
- OP0183 EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE (SSC-ILD): RESULTS FROM THE PHASE IIB RISE-SSC STUDY (2019) (6)
- COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study (2022) (6)
- Pulmonary Hypertension in Patients With COPD (2021) (6)
- The Hospital Anxiety and Depression Scale in patients with systemic sclerosis: a psychometric and factor analysis in a monocentric cohort. (2021) (6)
- Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database (2020) (5)
- COVAD survey 2 long-term outcomes: unmet need and protocol (2022) (5)
- [Common German language nomenclature for systemic sclerosis]. (2015) (5)
- Efficacy and Safety of Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease (SSc-ILD): Results from the Phase IIb RISE-SSc Study (2019) (5)
- NO evidence for an effect of the first COVID-19 lockdown on neck pain and neck disability among swiss office workers (2021) (5)
- Patient perception of disease burden in diffuse cutaneous systemic sclerosis (2019) (5)
- Pro-fibrotic phenotype of bone marrow stromal cells in Modic type 1 changes. (2021) (5)
- Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc) (2019) (5)
- Safety and efficacy of an intravenous loading dose of azathioprine for treatment of non-TPMT-deficient patients with rheumatic diseases. (2000) (5)
- Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study (2020) (5)
- Diagnostic measures for patients with systemic sclerosis-associated myopathy. (2021) (5)
- An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod (2021) (5)
- A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. (2021) (5)
- Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort (2022) (5)
- Cardiac manifestation of polyarteritis nodosa. (2018) (5)
- COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies (2022) (5)
- OP0249 LONG-TERM EXTENSION RESULTS OF RISE-SSC, A RANDOMIZED TRIAL OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) (2020) (5)
- Chemokines and chemokine receptors in the pathogenesis of systemic sclerosis (2002) (5)
- Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study (2021) (5)
- POS0054 THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS PATIENTS FROM THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR) (2021) (5)
- HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc (2002) (5)
- CD52 regulates monocyte adhesion and interferon type I signalling in systemic sclerosis patients. (2021) (4)
- An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis: The DETECT Study (2012) (4)
- cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis. (2020) (4)
- Prospective evaluation of the capillaroscopic skin ulcer risk index in systemic sclerosis patients in clinical practice: a longitudinal, multicentre study (2018) (4)
- A 30 year history of panniculitis. (2000) (4)
- TNFα induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNFα antibodies. (2021) (4)
- COVID-19 vaccination in autoimmune diseases (COVAD) Study: vaccine safety and tolerance in rheumatoid arthritis. (2022) (4)
- Dysregulated Expression of Arterial MicroRNAs and Their Target Gene Networks in Temporal Arteries of Treatment-Naïve Patients with Giant Cell Arteritis (2021) (4)
- rheumatism collaborative initiative rheumatology / European league against sclerosis : an American college of 2013 classification criteria for systemic (2013) (4)
- Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis (2015) (4)
- Gouty arthritis: Can we avoid unnecessary dual-energy CT examinations using prior radiographs? (2018) (4)
- FRI0303 THE EFFECTS OF RIOCIGUAT ON RAYNAUD’S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY (2019) (4)
- OP0083 INFECTIOUS AND AUTOINFLAMMATORY MODIC TYPE 1 CHANGES HAVE DIFFERENT PATHOMECHANISMS (2021) (4)
- OP0239 PROGRESSIVE LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN THE EUSTAR DATABASE (2019) (4)
- Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability (2021) (4)
- Pain chronification and the important role of non-disease-specific symptoms in patients with systemic sclerosis (2021) (4)
- Progress and Priorities in Systemic Sclerosis: The Next 10 Years – Report from the World Scleroderma Foundation (2016) (4)
- Faculty Opinions recommendation of Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. (2010) (4)
- Should Degenerated Intervertebral Discs of Patients with Modic Type 1 Changes Be Treated with Mesenchymal Stem Cells? (2022) (4)
- Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment (2022) (4)
- Animal Models of Scleroderma: From Cellular and Molecular Mechanisms to Novel Antifibrotic Strategies (2009) (4)
- OP0171 PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) (2021) (4)
- [Update in pulmonary hypertension associated with connective tissue diseases - a systematic literature review]. (2008) (4)
- Preservation of Lung Function Observed in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis (2019) (4)
- Systemic Sclerosis Classification Criteria: Developing methods for multi-criteria decision analysis with 1000Minds (2014) (4)
- High-resolution computed tomography of the chest for the screening, re-screening and follow-up of systemic sclerosis-associated interstitial lung disease: a EUSTAR-SCTC survey. (2021) (3)
- Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. (2022) (3)
- Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. (2019) (3)
- International, Prospective Registry For The Documentation Of First-line And Maintenance Therapy In Patients With Pulmonary Hypertension (CompERA-XL): Aims, Design, Methods, And Baseline Characteristics Of Patients (2010) (3)
- The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis (2018) (3)
- Disease course and outcome of progressive interstitial lung disease in systemic sclerosis (2019) (3)
- Vascular Mechanisms of Systemic Sclerosis (2018) (3)
- FRI0377 High rate of false negatives in the early detection of interstitial lung disease associated with systemic sclerosis by pulmonary function tests (2013) (3)
- Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. (2017) (3)
- Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire (2021) (3)
- Impaired micronutrients and prealbumin in patients with established and very early systemic sclerosis. (2020) (3)
- Lymphangiogenic factors are associated with pulmonary arterial hypertension in systemic sclerosis. (2021) (3)
- The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Instititial Lung Diseases: Subgroup with Autoimmune Diseases* (2020) (3)
- Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis (2021) (3)
- OP0284 Long Noncoding RNA MIR503HG is a Novel Factor in the Pathogenesis of Systemic Sclerosis (2015) (3)
- [Evidence-based therapy of Raynaud's syndrome]. (2006) (3)
- Heart involvement in patients with systemic sclerosis is mimicked by Fra-2 transgenic mice (2012) (3)
- Validation of the suction device Nimble for the assessment of skin fibrosis in systemic sclerosis (2020) (3)
- Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography (2022) (3)
- Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis (2019) (3)
- OP0115 EFFECT OF NINTEDANIB ON PROGRESSION OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED ILDS: FURTHER DATA FROM THE INBUILD TRIAL (2020) (3)
- Editorial: Precision Medicine in Chronic Inflammation (2021) (3)
- Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts (2022) (3)
- The effect of UVB on lupus skin: new light on the role of apoptosis in the pathogenesis of autoimmunity. (2006) (3)
- Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS Trial* (2019) (3)
- SAT0508 Ace-inhibitors in arterial hypertension in ssc patients display a risk factor for scleroderma renal crisis – a eustar analysis (2018) (3)
- MicroRNA-125b Regulates Fibroblast Apoptosis Proliferation in Systemic Sclerosis. (2019) (3)
- Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON (2022) (3)
- [Rheumatoid arthritis: new molecular and cellular aspects]. (1999) (3)
- Computed-tomography-based radiomics features for staging of interstitial lung disease – transferability from experimental to human lung fibrosis - a proof-of-concept study (2019) (3)
- Systemic sclerosis in the time of COVID-19 (2022) (3)
- THU0330 EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD) AND DIFFERING EXTENTS OF SKIN FIBROSIS: FURTHER ANALYSES OF THE SENSCIS TRIAL (2020) (3)
- Nintedanib Reduces Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Results of the SENSCIS Trial (2019) (2)
- S.13.1 Safety and efficacy of rituximab in SSc: an analysis from the European Scleroderma Trial and Research Group (2012) (2)
- Recent advances in the management of systemic sclerosis-associated interstitial lung disease (2022) (2)
- PU.1 controls fibroblast polarization and tissue fibrosis (2019) (2)
- Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database (2016) (2)
- The expression of inhibitor of differentiation-2 (Id-2) is induced by hypoxia in synovial fibroblasts independently of HIF-1a (2003) (2)
- Vaccination-based immunotherapy to target profibrotic cells in liver and lung. (2022) (2)
- ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. (2021) (2)
- Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials (2022) (2)
- Minimum information about a microarray experiment: comment on the editorial by Firestein and Pisetsky. (2003) (2)
- Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension Results of a systematic literature analysis by the EPOSS group (2010) (2)
- Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study. (2022) (2)
- A path to the future in scleroderma. (2008) (2)
- Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension (2022) (2)
- AB0209 Gli-Inhibitors Simultaneously Target Canonical and Non-Canonical Hedgehog Pathways and Ameliorate the Pro-Fibrotic Effects of Transforming Growth Factor-β (2015) (2)
- Reply to 'Dyslipidemia due to retroviral protease inhibitors' (2002) (2)
- AB0195 Type 2 Innate Lymphoid Cell Counts Are Increased in Patients with Systemic Sclerosis and Correlate with the Extent of Fibrosis (2015) (2)
- OP0211 Nintedanib Inhibits Fibroblast Activation and Ameliorates Fibrosis in Preclinical Models of Systemic Sclerosis (2015) (2)
- Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort. (2022) (2)
- Early and late pathological events in scleroderma (2011) (2)
- Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis. (2022) (2)
- Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial* (2019) (2)
- Mixed crystal-induced arthropathy--a rare finding. (2010) (2)
- The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort. (2021) (2)
- Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis (2008) (2)
- Promoter hypermethylation of the anti-fibrotic gene socs-3 by TGFβ as novel mechanism in the pathogenesis of SSc (2010) (2)
- Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib (2020) (2)
- FRI0402 Microrna-125b regulates apoptosis in systemic sclerosis (2018) (2)
- Assessment of Bone Mineral Density From a Computed Tomography Topogram of Photon-Counting Detector Computed Tomography—Effect of Phantom Size and Tube Voltage (2021) (2)
- OP0068 ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS— RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL (2019) (2)
- Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort (2022) (2)
- Individual functions of the histone acetyl transferases CBP and p300 in regulating the inflammatory response of synovial fibroblasts. (2021) (2)
- [Primary Sjögren's Syndrome - News on Diagnostics and Therapy]. (2020) (2)
- Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort. (2022) (2)
- FRI0265 Rituximab improves skin fibrosis and prevents worsening of lung function in patients with systemic sclerosis in the eustar cohort (2013) (2)
- FRI0240 HOSPITAL ANXIETY AND DEPRESSION SCALE AND SENSE OF COHERENCE 13-ITEM SCALE IN A SWISS COHORT OF SYSTEMIC SCLEROSIS PATIENTS: VALIDITY, RELIABILITY AND SENSITIVITY TO CHANGE (2020) (2)
- The inhibitor of differentiation-2 (Id-2) induced by hypoxia promotes bone de radation in rheumatoid arthritis (RA) (2004) (2)
- COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey (2022) (2)
- Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. (2020) (2)
- Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. (2021) (2)
- Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression? (2022) (2)
- FRI0575 BIOMARKER ANALYSIS FROM THE RISE-SSC STUDY OF RIOCIGUAT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC) (2020) (2)
- Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort (2022) (2)
- Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial (2022) (2)
- SAT0024 Increased production of leukotrienes by peripheral blood mononuclear cells is associated with more severe disease and worse prognosis in patients with systemic sclerosis (2013) (2)
- Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease (2020) (2)
- The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients (2020) (2)
- OP0142 Rituximab in systemic sclerosis : safety and efficacy data from the eustar network (2018) (2)
- Is there a role for nailfold videocapillaroscopy in interstitial lung disease? (2022) (2)
- Does angiotensin and endothelin receptor blockade have an impact on lung function? An analysis from the EUSTAR database. (2019) (1)
- Clinical images: Skin necrosis in giant cell arteritis. (1999) (1)
- FRI0365 New collagen biomarkers predict progression of fibrosis in systemic sclerosis (2017) (1)
- In systemic sclerosis, levels of tissue kallikrein are related to microvascular changes assayed by videocapillaroscopy and immunohistochemistry (2005) (1)
- Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. (2022) (1)
- Impact and outcome of COVID-19 on SSc-ILD (2021) (1)
- Vaccine hesitancy decreases, long term concerns remain in myositis, rheumatic disease patients: A comparative analysis of the COVAD surveys. (2023) (1)
- A3.19 mIR-193B induces UPA in SSC and contributes to the proliferative vasculopathy via uPAR independent pathways (2013) (1)
- Cohort enrichment strategies for progressive interstitial lung disease in systemic sclerosis from EUSTAR. (2022) (1)
- SAT0467 The Five Prospective Observational Trials of the International Systemic Sclerosis FP7-Health Research Project Desscipher: A Interim Report (2015) (1)
- Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by Time Since First Non-Raynaud Symptom: Subgroup Analysis of the SENSCIS Trial (2020) (1)
- OP0142 FIBROBLAST GROWTH FACTOR RECEPTOR 3 REGULATES THE ACTIVITY OF PROFIBROTIC CYTOKINE AND GROWTH FACTOR PATHWAYS TO DRIVE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SYSTEMIC SCLEROSIS (2020) (1)
- SAT0066 The long noncoding rna (LNCRNA) hottip is a master regulator of cell cycle in hand synovial fibroblasts in arthritis (2018) (1)
- Prediction and Frequency of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the World’s Largest Database of Patients with Systemic Sclerosis (EUSTAR) (2019) (1)
- OP0165 Joint-specific differences in the activation of the jak-stat pathway in rheumatoid arthritis (2018) (1)
- Eicosanoid production in the peripheral blood mononuclear cells (PBMC) from patients with systemic sclerosis (2008) (1)
- SAT0313 CORRELATION BETWEEN PROGRESSION OF SKIN FIBROSIS AND PROGRESSION OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH SSC-ILD: DATA FROM THE SENSCIS TRIAL (2020) (1)
- A rare disease patient-reported outcome measure: revision and validation of the German version of the Systemic Sclerosis Quality of Life Questionnaire (SScQoL) using the Rasch model (2021) (1)
- THU0392 Systemic sclerosis and primary biliary cholangitis: an overlap syndrome? preliminary data from a multicentre eustar study (2018) (1)
- AB0411 CHALLENGES IN THE MANAGEMENT OF MIXED CONNECTIVE TISSUE DISEASE: A RETROSPECTIVE ANALYSIS OF THE MCTD COHORT IN A TERTIARY REFERRAL CENTRE (2021) (1)
- Potential adipokine involvement in systemic sclerosis (2010) (1)
- FRI0369 Prospective evaluation of the capillaroscopic skin ulcer index (CSURI) in clinical practice (2017) (1)
- AB0553 THE NOCEBO PHENOMENON PARTLY ACCOUNTS FOR DIARRHOEA AMONG PARTICIPANTS IN THE RANDOMIZED PLACEBO-CONTROLLED TRIAL OF NINTEDANIB FOR INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS (SENSCIS) (2020) (1)
- Skin biomarkers associated with complex regional pain syndrome (CRPS) Type I: a systematic review (2022) (1)
- Effects of faecal microbiota transplantation on small intestinal mucosa in systemic sclerosis. (2023) (1)
- OP0269 A COMBINED CLINICAL AND BIOMARKER ALGORITHM TO PREDICT FVC DECLINE IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM AN INTERNATIONAL MULTICENTRE OBSERVATIONAL COHORT (2021) (1)
- Basic (PS01–PS58) (2012) (1)
- Length Double-blind , Randomized , 8-week Placebo-controlled followed by a 16-week open label extension study , with the LPA 1 receptor antagonist SAR 100842 for Patients With Diffuse Cutaneous Systemic Sclerosis (2018) (1)
- SAT0434 Does Angiotensin and Endothelin Receptor Blockade Have an Impact on Lung Function? an Analysis from the Eustar Data Base (2015) (1)
- FRI0301 GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH NINTEDANIB: DATA FROM THE SENSCIS TRIAL (2019) (1)
- Meeting abstracts from the 9th International Conference on cGMP: Generators, Effectors and Therapeutic Implications (2019) (1)
- Visual assessment of digital ulcers in systemic sclerosis analysed by eye tracking: implications for wound assessment. (2020) (1)
- The enigma of mixed connective tissue disease—challenges in routine care (2022) (1)
- SAT0204 The Eular Systemic Sclerosis Impact of Disease (ScleroID) Score – A New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis under Development (2016) (1)
- Evaluation of 99 mTc-rhAnnexin V-128 SPECT / CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis (2018) (1)
- Effect of imatinib mesylate (IM) on endothelial cells (EC) functions (2008) (1)
- Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan (2013) (1)
- A comprehensive single-cell atlas of freshly dissociated human synovium in inflammatory arthritis with an optimized dissociation protocol for prospective fresh synovial biopsy collection (2022) (1)
- AB0698 MID-Term Effects of Rituximab in Connective Tissue Disorders Related Interstitial Lung Disease (ILD) (2015) (1)
- Systemic Sclerosis Associated Interstitial Lung Disease: A Conceptual Framework for Subclinical, Clinical, and Progressive Disease. (2022) (1)
- OP0017 NINTEDANIB REDUCED DECLINE IN FORCED VITAL CAPACITY ACROSS SUBGROUPS OF PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: DATA FROM THE SENSCIS TRIAL (2019) (1)
- Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: an EUSTAR database analysis. (2022) (1)
- Sacroiliac joint radiographic progression in axial spondyloarthritis is retarded by the therapeutic use of TNF inhibitors: 12-year data from the SCQM registry (2022) (1)
- [Angiogenesis. Possibilities for therapeutic intervention in rheumatic diseases]. (2007) (1)
- Resolving phenotypic and prognostic differences in interstitial lung disease related to systemic sclerosis by computed tomography-based radiomics (2020) (1)
- FRI0516 Paquinimod (ABR-215757), an Immunomodulatory Compound, Reduces Fibrosis in the Tight Skin-1 (TSK-1) Model for Systemic Sclerosis (2014) (1)
- Developing A Disease Activity And Therapeutic Response Index In Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Consensus On Domains (2012) (1)
- SAT0474 Racial differences in ssc disease presentation: a european scleroderma trials and research group study (2018) (1)
- World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease (2022) (1)
- THU0425 18f-fluorodeoxyglucose positron emission tomography/computed tomography and lung involvement in systemic sclerosis (2018) (1)
- Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. (2022) (1)
- Abstract 37: Machine Learning Analysis Of Connective Tissue Networks Enables Objective Characterization Of Skin Fibroses (2019) (1)
- POS0318 CLINICAL PHENOTYPE IN SCLERODERMA PATIENTS WITH ANTI-TOPOISOMERASE I POSITIVITY AND LIMITED CUTANEOUS FORM: DATA FROM THE EUSTAR DATABASE (2021) (1)
- AB0413 HIGH-RESOLUTION COMPUTED TOMOGRAPHY FOR THE SCREENING, RE-SCREENING AND FOLLOW-UP OF SYSTEMIC SCLEROSIS RELATED INTERSTITIAL LUNG DISEASE: RESULTS OF A EUSTAR-SCTC SURVEY (2021) (1)
- OP0157 Apoptosis resistance of synovial fibroblasts of patients with rheumatoid arthritis is regulated by the long non-coding rna fas-as1 (2017) (1)
- [Systemic sclerosis]. (2008) (1)
- Novel aspects in the epidemiology, pathophysiology and treatment of connective tissue diseases. Introduction. (2006) (1)
- Diffuse myocardial fibrosis precedes subclinical functional myocardial impairment and provides prognostic information in systemic sclerosis. (2022) (1)
- OP0290 HOTAIR IS INVOLVED IN JOINT PATTERNING BY REGULATING FGFR2, BMP2 AND WNT PATHWAYS (2019) (1)
- Self-monitoring of the resting heart rate using a fitness tracker smartwatch application leads to an early diagnosis of large vessel vasculitis (2022) (1)
- Rapid Growth of Lung Nodules due to Combined Pulmonary Vasculitis, Silicoanthracosis, and Chondrocalcinosis (2016) (1)
- Representativeness of Systemic Sclerosis Patients in Interventional Randomized Trials: an analysis of the EUSTAR database. (2021) (1)
- Regulation of eicosanoid production in peripheral blood mononuclear cells from patients with systemic sclerosis (2007) (1)
- OP0150 MACHINE LEARNING APPROACHES FOR RISK MODELLING IN INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS USING HIGH DIMENSIONAL IMAGE ANALYSIS (2021) (1)
- THU0252 Nailfold capillaroscopy in systemic lupus erythematosus: a systematic review and critical appraisal (2017) (1)
- Overexpression of specific autoantigens in scleroderma fibroblasts (2002) (0)
- Overexpression of Vascular Endothelial Growth Factor (VEGF) in Systemic Sclerosis (SSc) : Role of the Hypoxia Inducible Transcriptionfactor HIF-1 α and Evidence for Protective Effects of VEGF Against the Development of Fingertip Ulcers (2001) (0)
- FRI0144 JOINT-SPECIFIC RESPONSES TO TOFACITINIB AND ADALIMUMAB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STANDARD AND ORAL STRATEGY (2019) (0)
- THU0356 STAPHYLOCOCCUS AUREUS REGULATES FIBROBLAST FUNCTIONS – IMPLICATIONS FOR TISSUE REPAIR IN CHRONIC DIGITAL ULCERS IN SYSTEMIC SCLEROSIS (2019) (0)
- The role of the bone in Complex Regional Pain Syndrome 1 - A systematic review. (2023) (0)
- THU0400 Incidence and risk factors for gangrene in patients with systemic sclerosis from the eustar cohort (2018) (0)
- OP0248 DEVELOPMENT OF A 3D SKIN MICROTISSUE MODEL FOR FIBROTIC DISEASES (2021) (0)
- Anti–Tumor Necrosis Factor-&agr; Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis (2002) (0)
- SAT0333 SERUM METABOLITES AS BIOMARKERS IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (2020) (0)
- Activation of Hedgehog signalling plays a crucial role in the pathogenesis of systemic sclerosis (2010) (0)
- POS0428 REGULATION OF IFN SIGNATURE BY HDAC CLASS IIa-CD52 AXIS IN SYSTEMIC SCLEROSIS (2021) (0)
- THU0395 Influence of setting an upper limit of the mrss as an inclusion criterion in ssc clinical trials on the ratio of skin fibrosis progression vs. improvement – an analysis of the genisos cohort (2018) (0)
- Double-blind , Randomized , 8-week Placebo-controlled followed by a 16-week open label extension study , with the LPA 1 receptor antagonist SAR 100842 for Patients With Diffuse Cutaneous Systemic Sclerosis (2019) (0)
- Faculty Opinions recommendation of Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. (2012) (0)
- OP0242 SAFETY PROFILE OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS (2019) (0)
- THU0013 INTEGRATED ANALYSIS OF SYNOVIAL SINGLE CELL RNA SEQUENCING DATA DEEPENS THE CURRENT KNOWLEDGE OF SYNOVIAL PATHOLOGY IN ARTHRITIS (2020) (0)
- Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and 2 surveys. (2023) (0)
- Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension (2023) (0)
- The AP-1 transcription factor Fosl-2 drives cardiac fibrosis and arrhythmias under immunofibrotic conditions (2023) (0)
- Management of Scleroderma-Associated Pulmonary Involvement (2015) (0)
- HISTOMORPHOMETRY OF MODIC CHANGES (2020) (0)
- AB0837 Circulating micrornas in systemic sclerosis patients reflect microrna profile of cultured scleroderma fibroblasts and correlate with distinct disease features (2013) (0)
- Pulmonary arterial hypertension in connective tissue (2012) (0)
- Bromodomain Protein Inhibitors Reorganize the Chromatin of Synovial Fibroblasts (2023) (0)
- Corrigendum to: Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort (2022) (0)
- SAT0198 The Desscipher Project in Systemic Sclerosis (SSC): Observational Data on Digital Ulcers (DU) Prevention from The Eustar Group (2016) (0)
- Faculty Opinions recommendation of Interstitial lung disease in systemic sclerosis: a simple staging system. (2008) (0)
- IL-21R mRNA is overexpressed in systemic sclerosis and contributes to the epidermal/dermal cross-talk (2003) (0)
- Abstracts from the 4th Systemic Sclerosis World Congress February 18–20, 2016 - Lisbon, Portugal (2016) (0)
- Vision transformer assisting rheumatologists in screening for capillaroscopy changes in systemic sclerosis: an artificial intelligence model. (2022) (0)
- The Role and Function of Monocyte-Derived Fibroblast-like Cells in Multi-Organ Fibrosis in Systemic Sclerosis (2017) (0)
- P065 Post COVID-19 Syndrome in patients with autoimmune rheumatic diseases: Results from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study (2023) (0)
- OP0083 Molecular targeted imaging biomarkers for personalized medicine strategies in systemic sclerosis-related interstitial lung disease (2017) (0)
- A Multi-component Intervention (NEXpro) Reduces Neck Pain-Related Work Productivity Loss: A Randomized Controlled Trial Among Swiss Office Workers (2022) (0)
- FRI0390 European multicentre study validates elf test as biomarker of fibrosis in systemic sclerosis (2017) (0)
- Exercise pulmonary hemodynamics in systemic sclerosis patients – Implications for outcome (2016) (0)
- Acrylonitrile and Pullulan Based Nanofiber Mats as Easily Accessible Scaffolds for 3D Skin Cell Models Containing Primary Cells (2022) (0)
- THU0345 TEXTURE-BASED RADIOMICS FEATURES DISCRIMINATE DIFFERENT STAGES OF EXPERIMENTAL INTERSTITIAL LUNG DISEASE (2019) (0)
- S.5.5 FEATURES OF SSc PATIENTS WITH INAPPROPRIATE EXERCISE-INDUCED INCREASE IN PULMONARY ARTERY PRESSURE ESTIMATED BY ECHOCARDIOGRAPHY (2012) (0)
- Iron Deficiency and Incident Infections among Community-Dwelling Adults Age 70 Years and Older: Results from the DO-HEALTH Study (2022) (0)
- The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort. (2023) (0)
- OP0206 Fra2 Is Playing A Key Role in The Control of Treg Development and Autoimmunity (2016) (0)
- Liposomal aggregates sustain the release of rapamycin and protect cartilage from friction (2023) (0)
- Incidence of new pulmonary hypertension and determining factors during follow-up of patients with systemic sclerosis after negative right heart catheterisation (2017) (0)
- THU0451 CELL-MATRIX ADHESION OF BONE MARROW STROMAL CELLS IN MODIC TYPE 1 CHANGES IS INCREASED AND RELATES TO INCREASED EXPRESSION OF INTEGRIN Β1 (2020) (0)
- Identification of a New Set of Activity Criteria for Systemic Sclerosis. Preliminary Report (2015) (0)
- HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry (2022) (0)
- A8.3 Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model (2013) (0)
- POS0835 DECLINE IN FORCED VITAL CAPACITY (FVC) IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL VERSUS HYPOTHETICAL REFERENCE SUBJECTS WITHOUT LUNG DISEASE (2021) (0)
- S.10.1 FRA-2 transgenic mice display the main features of SSC-associated pulmonary hypertension in a PDGF-BB/PDGFR pathway dependent manner (2012) (0)
- FRI0325 IDENTIFYING SYSTEMIC SCLEROSIS PATIENTS AT RISK OF PROGRESSIVE LUNG FIBROSIS – A EUSTAR DATABASE ANALYSIS (2019) (0)
- OP0221 OLIGOMERIC S100A4 INDUCES MONOCYTE INNATE IMMUNE MEMORY (2019) (0)
- Sustained mechanical tension governs fibrogenic activation of tendon stromal cells in systemic sclerosis (2021) (0)
- SAT0292 INTEGRATIVE TRANSCRIPTOMIC AND FUNCTIONAL ANALYSIS REVEALS A ROLE OF DIMETHYL-Α-KETOGLUTARATE IN TGFΒ-DRIVEN CYTOSKELETON REGULATION AND MYOFIBROBLAST DIFFERENTIATION (2020) (0)
- European consensus statements for interstitial lung disease in systemic sclerosis – Authors' reply (2020) (0)
- AB0431 EXPLORING THE UTILITY OF THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CRISS IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (2021) (0)
- Faculty Opinions recommendation of Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. (2007) (0)
- OP0272 68GA-FAPI-04 PET/CT STUDY EXTENSION FOR THE ASSESSMENT OF FIBROBLAST ACTIVATION AND RISK EVALUATION IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE (2021) (0)
- OP0096 DYSREGULATED BONE MARROW STROMAL CELLS IN MODIC TYPE 1 CHANGES (2019) (0)
- Gene transfer of protective cytokines in rheumatoid arthritis. (2001) (0)
- SP0212 Hypoxia, Fibroblasts and Systemic Sclerosis (2014) (0)
- SAT0366 Smoking behaviour and the progression of organ manifestations in systemic sclerosis: a longitudinal european scleroderma trials and research group study (2017) (0)
- POS0321 USE OF HYDROXYCHLOROQUINE AND SYSTEMIC SCLEROSIS: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY ON THE EUSTAR COHORT (2021) (0)
- SAT0652-HPR CHRONIC DISEASE MANAGEMENT AND HEALTH TECHNOLOGY READINESS OF PATIENTS WITH SYSTEMIC SCLEROSIS IN SWITZERLAND – A CROSS-SECTIONAL STUDY (2020) (0)
- SAT0287 AMPLIFICATION OF THE PRO-FIBROTIC JAK2-STAT3 SIGNALING AXIS BY TGFΒ-INDUCED EPIGENETIC SILENCING OF SOCS3 (2020) (0)
- [A rare differential diagnosis of "atraumatic" shoulder pain]. (2020) (0)
- SAT0511 Practical suggestions on intravenous iloprost in raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus (2018) (0)
- Novel tools for molecular analysis in synovium (2003) (0)
- OP0020 HOMEOBOX D TRANSCRIPTION FACTORS SHAPE DIFFERENTIAL JOINT ENVIRONMENT BETWEEN ANTERIOR FINGER JOINTS AND THUMB (2021) (0)
- FRI0358 99MTC-RHANNEXIN V-128 as a novel early diagnostic marker for interstitial lung disease associated with systemic sclerosis (2017) (0)
- Targeting the HIF system (2001) (0)
- OP0186 LIN-GP38+ STROMAL CELLS ARE KEY EFFECTOR CELLS IN MYOCARDIAL FIBROSIS AND DEFECTS OF THE CONDUCTION SYSTEM (2019) (0)
- SAT0055 JOINT SPECIFIC TNF RESPONSE OF SYNOVIAL FIBROBLASTS IN RHEUMATOID ARTHRITIS (2019) (0)
- USE OF IMMUNOSUPPRESSANTS IN SSC PATIENTS WITH INTERSTITIAL LUNG DISEASE - RESULTS OF THE DESSCIPHER PROJECT OF THE EUSTAR GROUP (2014) (0)
- Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis (2023) (0)
- FRI0247 The Involvement of The Long Noncoding H19x in tGFβ Signaling and Its Profibrotic Effects in Systemic Sclerosis and Other Fibrotic Diseases (2016) (0)
- Systemic Sclerosis-Related Myopathy (2020) (0)
- SAT0273 PREDICTIVE VALUE OF THE REVISED EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP ACTIVITY INDEX (EUSTAR-AI) (2019) (0)
- OP0252 CIRCULATING COLLAGEN TURNOVER MARKERS ARE SPECIFICALLY CHANGED IN VERY EARLY SYSTEMIC SCLEROSIS (2020) (0)
- Response to: ‘Riociguat in systemic sclerosis: a potential for disease modification’ by Jain and Dhir (2020) (0)
- 09 Lessons from scleroderma: treatment of interstitial lung disease in SLE (2021) (0)
- SAT0264 GAZE PATTERN ANALYSIS IN THE ASSESSMENT OF DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS (2019) (0)
- 1 Profile of gastrointestinal involvement in patients with systemic sclerosis (2017) (0)
- Doppler ultrasound measurement of digital blood flow in systemic sclerosis (1998) (0)
- Proteasome inhibition restored the reduced expression of fibroblast growth factor receptor 3 in rheumatoid arthritis synovial fibroblasts (2020) (0)
- AB0840 Scleroderma classification criteria: Disease-specific methods for valid case comparisons (2013) (0)
- Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey (2023) (0)
- Promising anti-fibrotic approaches for future treatment of systemic sclerosis. (2010) (0)
- Mhealth Tool Development For Patient Home-Based Wound Documentation (2019) (0)
- SAT0234 RNA SEQUENCING IDENTIFIES AN IGA VASCULITIS ASSOCIATED SERUM MICRORNA SIGNATURE, DISCRIMINATING PATIENTS WITH IGA VASCULITIS FROM AGE- AND SEX-MATCHED HEALTHY SUBJECTS (2019) (0)
- POS0861 EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT (2021) (0)
- Sex-specific difference in cardiac function in patients with systemic sclerosis: association with cardiovascular outcomes (2021) (0)
- THU0006 PROINFLAMMATORY RESPONSES IN THE JAK-STAT PATHWAY IN SYNOVIAL FIBROBLASTS ARE STIMULUS-SPECIFIC AND ONLY PARTIALLY INHIBITED BY THERAPEUTIC DOSES OF TOFACITINIB (2019) (0)
- Efficacy of retroviral gene transfer into synovial fibroblasts is reduced by co-transduction with adenoviral vectors (2002) (0)
- P126 Epigenetic control of distally expressed hoxd genes in synovial fibroblasts (2018) (0)
- OP0038 IMPROVING RISK-STRATIFICATION OF RHEUMATOID ARTHRITIS PATIENTS FOR INTERSTITIAL LUNG DISEASE (2020) (0)
- Faculty Opinions recommendation of Cigarette smoking in patients with systemic sclerosis. (2011) (0)
- SAT0473 Clinical and echocardiographic associates of all-cause mortality and cardiovascular outcomes in patients with systemic sclerosis (2018) (0)
- Response to: ‘ Correspondence on ‘Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension’’ by Iudici et al (2020) (0)
- Response to: ‘Will SPAR be useful in the usual patients with scleroderma?’ by Chattopadhyay et al (2018) (0)
- Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomes (2023) (0)
- OP0088 The role and function of monocyte-derived fibroblast-like cells in multi-organ fibrosis in systemic sclerosis (2017) (0)
- FRI0420 Altered transcriptome of circulating cd14+ monocytes in systemic sclerosis (2018) (0)
- The inhibitor of helix-loop-helix transcription factor ID-2 triggered by hypoxia and proinflammatory cytokines promotes the activated phenotype of synovial fibroblasts facilitating bone degradation (2004) (0)
- Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects (2022) (0)
- POS0855 PATIENT PREFERENCES, TRADE-OFFS AND ACCEPTABLE RISKS IN THE TREATMENT OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A STEP TOWARDS SHARED DECISION-MAKING (2021) (0)
- OP0018 Microrna-145 down-regulation in systemic sclerosis is limited to skin fibroblasts and influenced by epigenetic modifications and negative feedback loop by TGF-β (2013) (0)
- Erratum to the impact of slice-reduced computed tomography on histogram based densitometry assessment of lung fibrosis in patients with systemic sclerosis. (2019) (0)
- Author Correction: Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis (2017) (0)
- POS0316 MODELLING SHORT-TERM FVC CHANGES FROM SENSCIS TO LONG-TERM FVC COURSE IN SSc-ILD DEMONSTRATES CLINICALLY MEANINGFUL REDUCTION OF FVC DECLINE AND SURVIVAL BENEFITS (2021) (0)
- FRI0265 IS AN IMPROVEMENT IN SKIN FIBROSIS ASSOCIATED WITH BETTER OUTCOME IN PATIENTS WITH SYSTEMIC SCLEROSIS? A EUSTAR ANALYSIS (2020) (0)
- OP0326 Epigenetically-driven distal expression of the lncrna hottip shapes inflammatory, adhesive and proliferative characteristics of hand synovial fibroblasts in arthritis (2017) (0)
- Faculty Opinions recommendation of Prevalence of Barrett's esophagus in systemic sclerosis. (2006) (0)
- POS0332 ENDOTHELIAL ACTIVATION IN SYSTEMIC SCLEROSIS VASCULOPATHY: ROLE OF LONG NON-CODING RNA H19X (2021) (0)
- OP0184 PROFIBROTIC LNCRNA H19X: UNRAVELLING THE EFFECTS ON CHROMATIN REMODELING IN SYSTEMIC SCLEROSIS FIBROBLASTS (2019) (0)
- AB0433 STUDY DESIGN FOR THE RANDOMISED CONTROLLED PHASE II ReSScue TRIAL: SAFETY AND EFFICACY OF FAECAL MICROBIOTA TRANSPLANTATION BY ANAEROBIC CULTIVATED HUMAN INTESTINAL MICROBIOME (ACHIM) IN PATIENTS WITH SYSTEMIC SCLEROSIS (2021) (0)
- Cohort and Possible Recommendations for Screening Systemic Sclerosis : Analysis of the EULAR Scleroderma Trials and Research Malignancies in Patients with Anti-RNA Polymerase III Antibodies and (2017) (0)
- Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period - A Cross-sequential study based on COVAD surveys. (2023) (0)
- SAT0439 Prediction of Improvement in Skin Fibrosis in Diffuse Cutaneous Systemic Sclerosis – a Eustar Analysis (2015) (0)
- Feasibility and Efficacy of Cohort Enrichment for Progressive Lung Fibrosis in Systemic Sclerosis - a EUSTAR Database Analysis (2019) (0)
- Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. (2023) (0)
- FRI0049 Surface proteins on microparticles can induce resistance of rheumatoid arthritis synovial fibroblasts to apoptosis mediated by death receptors (2013) (0)
- Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study (2023) (0)
- Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management Registry (2023) (0)
- Innovative Approaches to Clinical Trials in Systemic Sclerosis (2017) (0)
- THU0092 The l1 mrna in rheumatoid arthritis encodes a functional retrotransposable element (2001) (0)
- Systemic Sclerosis 2011 (2012) (0)
- POS0328 ENGRAILED 1 COORDINATES CYTOSKELETAL ORGANIZATION TO PROMOTE MYOFIBROBLAST DIFFERENTIATION AND FIBROTIC TISSUE REMODELING (2021) (0)
- Call for papers: Sex and gender in rheumatology (2022) (0)
- O020 Long noncoding RNA H19X is a master regulator of extracellular matrix production in systemic sclerosis (2018) (0)
- POS0317 THE PERFORMANCE OF DIFFUSING CAPACITY FOR MONOXIDE CARBON (DLCO) AND FORCED VITAL CAPACITY (FVC) IN PREDICTING THE ONSET OF SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD) IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE (2021) (0)
- Faculty Opinions recommendation of Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. (2009) (0)
- THU0343 PU.1 INHIBITOR DB1976 CONTROLS FIBROBLAST POLARIZATION IN SYSTEMIC SCLEROSISAND LEADS TO REGRESSION OF FIBROSIS IN DIFFERENT MODELS OF ORGAN FIBROSIS (2019) (0)
- OP0231 Heart involvement in scleroderma patients and mice models (2013) (0)
- Author Correction: Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis (2021) (0)
- POS0866 TWO-DIMENSIONAL HRCT-BASED RADIOMIC FEATURES IN SSC-ILD DISTINGUISH DRUG RESPONDERS FROM NON-RESPONDERS (2021) (0)
- Prediction of histology by B-mode and PD-mode ultrasound across different joint locations and diseases (2022) (0)
- THU0409 Management of systemic sclerosis (SSC) related digital ulcers (DU) in expert tertiary centres: results from the analysis of the multicentre observational real-life desscipher/eustar study (2018) (0)
- Faculty Opinions recommendation of CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. (2008) (0)
- Calcineurin inhibitors in systemic sclerosis – a systematic literature review (2022) (0)
- O011 Why joint location matters in the pathogenesis of rheumatoid arthritis (2018) (0)
- FRI0456 Predictors for disease worsening defined by organ failure in diffuse systemic sclerosis: a european scleroderma trials and research (EUSTAR) analysis (2018) (0)
- FGF2 overrides key pro-fibrotic features of bone marrow stromal cells isolated from Modic type 1 change patients. (2022) (0)
- A systematic literature review- Calcineurin inhibitors treatment in systemic sclerosis (2021) (0)
- Role of C‐reactive protein in the bone marrow of Modic type 1 changes (2022) (0)
- Rheumatoid arthritis: basic mechanisms in joints (2018) (0)
- FRI0446 Severe Heart Disease in Systemic Sclerosis: Prevalence, Risk Factors and Current Treatment. A Eustar-Desscipher Study (2015) (0)
- FRI0269 Diffuse Cutaneous Systemic Sclerosis (dcSSc) Referral and Diagnosis: Results of A Survey of Healthcare Providers (2016) (0)
- THU0038 INDIVIDUAL FUNCTIONS OF THE HISTONE-ACETYLTRANSFERASES CBP AND P300 IN REGULATING THE INFLAMMATORY RESPONSE OF RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS (2019) (0)
- THU0114 The Loss of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFtg Mouse Model (2013) (0)
- 5-HT release from platelets and activation of 5-HT2B play a crucial role for development of fibrosis in systemic sclerosis (2010) (0)
- S.6.1 β-catenin is a central mediator in SSc (2012) (0)
- SAT0310 ANTI-CENTROMERE ANTIBODY ISOTYPE LEVELS AS BIOMARKER FOR DISEASE PROGRESSION IN SUBJECTS AT RISK TO DEVELOP SYSTEMIC SCLEROSIS (2020) (0)
- In depths discussion: Potential vascular and fibrotic targets for drug intervention (2011) (0)
- Author Correction: Chromatin accessibility landscapes of skin cells in systemic sclerosis nominate dendritic cells in disease pathogenesis (2020) (0)
- [Systemic sclerosis. Objectives for the treatment]. (2009) (0)
- Autoimmune multimorbidity and fatigue in women with idiopathic inflammatory myopathies: an international, patient-reported, e-survey (2022) (0)
- SAT0227 The Efficacy of Vasoactive and Vasodilating Drugs on Digital Ulcers Healing in Systemic Sclerosis: Data from The Desscipher Observational Study of Eustar Group (2016) (0)
- OA29 Flares following COVID-19 vaccination in patients with idiopathic inflammatory myopathies: combined analysis from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) studies (2023) (0)
- Does HCMV infection trigger the vascular damage in SSc? (2000) (0)
- POS0333 ALTERED MACROPHAGE POLARIZATION PHENOTYPES IN SYSTEMIC SCLEROSIS (2021) (0)
- Modic type 2 changes are fibroinflammatory changes with complement system involvement adjacent to degenerated vertebral endplates (2022) (0)
- 04. Outcomes, Quality of Life, Psychological & Social (2018) (0)
- [Systemic Autoimmune Diseases - Challenges for the Daily Practice]. (2020) (0)
- AB0627 Rise-ssc: a double-blind, randomised study evaluating the efficacy and safety of riociguat for the treatment of patients with diffuse cutaneous systemic sclerosis (2017) (0)
- FRI0416 Xiap as novel integrator of tgf Βeta signalling and canonical wnt signalling in tissue fibrosis (2018) (0)
- Developing a Disease Activity and Therapeutic Response Index in Connective Tissue Disease Related Interstitial Lung Disease: Initial Results of a Delphi Exercise (2011) (0)
- FRI0248 Predictors of Disability in Systemic Sclerosis: A Study from The Desscipher Project (2016) (0)
- POS0368 CITRULLINATION INDUCES EPIGENETIC MEMORY OF THE INNATE IMMUNE SYSTEM (2021) (0)
- Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis (2021) (0)
- Sex difference in left ventricular global longitudinal strain in patients with systemic sclerosis: association with outcomes (2020) (0)
- OP0034 Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the detect cohort (2017) (0)
- Biomarkers of Fibrosis (2012) (0)
- Response to: ‘Can we further SPARkle the SPAR model?’ by Kavadichanda et al (2018) (0)
- [Septic arthritis? Gonococcal infection despite negative bacterial cultures]. (2008) (0)
- Session 4: An Integrated Approach to Gastro-intestinal Involvement (2014) (0)
- Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database. (2022) (0)
- Author Correction: The AP-1 transcription factor Fosl-2 drives cardiac fibrosis and arrhythmias under immunofibrotic conditions (2023) (0)
- [Systemic sclerosis-clinical picture, diagnosis, and treatment]. (2019) (0)
- THU0351 MUSCLE INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ANTI-PM/SCL+ ANTIBODIES IS ASSOCIATED WITH CARDIAC AND PULMONARY INVOLVEMENT. ANALYSIS OF THE MULTICENTRE EUSTAR COHORT. (2020) (0)
- Progression of Skin Fibrosis Is Associated with Decline in Lung Function in Patients with Diffuse Cutaneous Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis (2019) (0)
- Review Hypoxia Hypoxia in the pathogenesis of systemic sclerosis (2009) (0)
- OP0251 THE EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (SCLEROID) SCORE – A NEW PATIENT-REPORTED OUTCOME MEASURE FOR PATIENTS WITH SYSTEMIC SCLEROSIS (2020) (0)
- Serotonin and Fibrosis (2021) (0)
- Antibodies against periodontal pathogens are not associated with joint swelling or autoimmunity associated with RA in a cohort of healthy individuals at increased risk of rheumatoid arthritis (2015) (0)
- Implications of angiogenic heterogeneity (2000) (0)
- SAT0481 Setting the standard for longitudinal follow-up of systemic sclerosis; a eustar delphi-based expert consensus (2018) (0)
- OP0242 META-ANALYSIS OF SINGLE-CELL RNA SEQUENCING DATA OF THE SYNOVIUM TO DEFINE SYNOVIAL FIBROBLAST PHENOTYPES ACROSS JOINT LOCATION AND DISEASE (2020) (0)
- Diffuse myocardial fibrosis precedes impairment of myocardial strain in patients with systemic sclerosis (2021) (0)
- FRI0468 Abnormal oesophageal motility during a solid test meal in systemic sclerosis – detection in very early disease and association with disease progression (2018) (0)
- FRI0461 Immunosuppressive “Routine” Treatment of of SSC Patients with Interstitial Lung Disease – Results of the FP7 Desscipher Project of the Eustar Group (2015) (0)
- FRI0270 Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis (DcSSc) (2016) (0)
- OP0181 Vegf induces vasculopathy and fibrosis in vivo closely resembling human systemic sclerosis (2013) (0)
- FRI0471 Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the spar model (2018) (0)
- SAT0186 The Homeoprotein Engrailed-1 Regulates Canonical TGF-β Signaling via Fibroblast Differentiation and Tissue Fibrosis (2016) (0)
- SAT0318 Epigenetic regulation of FRA2 by JMJD3 regulates fibroblast activation in systemic sclerosis (2017) (0)
- AB1272 ONLINE EDUCATION BOOSTS CLINICIAN KNOWLEDGE ABOUT EMERGING THERAPIES FOR PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (2020) (0)
- OP0229 MIR-193B Induces uPA in SSC and Contributes to the Proliferative Vasculopathy Via uPAR Independent Pathways (2013) (0)
- Modelling Short-Term FVC Changes from SENSCIS to Long-Term FVC Course in SSc-ILD Demonstrates Clinically Meaningful Reduction of FVC Decline and Survival Benefits (0)
- POS0877 THE EFFECT OF PLATELET INHIBITORS ON DIGITAL ULCERS IN SYSTEMIC SCLEROSIS - A DERIVATION AND VALIDATION EUSTAR STUDY (2021) (0)
- Markers of tumor endothelium-Implications for anti-angiogenic therapies (2000) (0)
- Microparticles from inflammatory cells are strong inducers of matrix metalloproteinases and inflammatory cytokines in synovial fibroblasts (2005) (0)
- AB0637 IS VERY EARLY SYSTEMIC SCLEROSIS (SSC) A COMBINATION OF MILD AND EARLY DISEASE? (2019) (0)
- Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study. (2023) (0)
- Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study (2022) (0)
- OP0016 IDENTIFICATION OF FUNCTIONAL VARIANTS IN THE RHEUMATOID ARTHRITIS ASSOCIATED JAZF1 LOCUS IN SYNOVIAL FIBROBLASTS (2021) (0)
- The inhibitor of differentiation-2 promotes synovial fibroblast-dependent osteoclastogenesis in rheumatoid arthritis (2005) (0)
- THU0331 INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: DECLINE IN FORCED VITAL CAPACITY DOES NOT PREDICT FURTHER PROGRESSION IN THE FOLLOWING PERIOD (2020) (0)
- OP0144 Intravenous versus oral cyclophosphamide (CYC) for the treatment of interstitial lung involvement (ILD) and skin involvement in systemic sclerosis (SSC): safety and efficacy evaluation in a large multi-centre scleroderma cohort (2018) (0)
- SAT0291 THE ROLE OF X-LINKED INHIBITOR OF APOPTOSIS PROTEIN (XIAP) IN SYSTEMIC SCLEROSIS (2020) (0)
- Pathophysiology of systemic sclerosis (2013) (0)
- Microparticles may contribute to the pathogenesis of systemic lupus erythematosus (2008) (0)
- Serum levels of vascular endothelial growth factor (VEGF) according to disease duration (2011) (0)
- CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY HYPERTENSION AND A PULMONARY CAPILLARY WEDGE PRESSURE >15 IN THE PHAROS REGISTRY (2014) (0)
- S.11.1 Influence of digital ulcer healing on disability and daily activity limitations in SSc (2012) (0)
- 05.11 Antisense long noncoding rnas are deregulated in skin tissue of ssc patients (2017) (0)
- [Cardiovascular manifestations in rheumatoid arthritis]. (2005) (0)
- 056. CHARACTERISTICS BY AUTOANTIBODY STATUS IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: THE EUROPEAN SCLERODERMA OBSERVATIONAL STUDY COHORT (2017) (0)
- OP0330 FRA2 overexpression leads to systemic autoimmunity by decreasing IL-2 responsiveness and thymic treg development (2017) (0)
- [Systemic sclerosis-clinical picture, diagnosis, and treatment]. (2019) (0)
- OP0185 INFLAMMATION-DEPENDENT DECREASED EXPRESSION OF CD52 ON CIRCULATING CD14+ MONOCYTES FACILITATES ADHESION IN SYSTEMIC SCLEROSIS (2019) (0)
- FRI0356 Antisense long noncoding rnas are deregulated in skin tissue of ssc patients (2017) (0)
- [Early stage connective tissue diseases]. (2013) (0)
- FRI0263 Nodular Regenerative Hyperplasia of The Liver – A Rare Vascular Complication of SSC (2016) (0)
- P4534Reduced right ventricular contractile reserve in patients with systemic sclerosis and borderline pulmonary arterial pressures (2018) (0)
- SAT0254 VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY (2019) (0)
- Treatment aims in rheumatoid arthritis (2018) (0)
- Rheumatoid Synovium Activation of the IL-4 STAT Pathway in (2000) (0)
- Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis — Source link (0)
- FRI0267 CLINICAL CORRELATES AND RELEVANCE OF UCLA GIT 2.0 FOR ESOPHAGITIS AND INDICATION FOR ESOPHAGOGASTRODUODENOSCOPY IN REAL-LIFE PATIENTS WITH SYSTEMIC SCLEROSIS (2020) (0)
- SAT0328 OUTCOME OF INTERSTITIAL LUNG DISEASE (ILD) IN ANTI-PM/SCL PATIENTS WITH SYSTEMIC SCLEROSIS: RESULTS FROM AN EUSTAR CASE-CONTROL STUDY. (2020) (0)
- CD4 as a receptor for IL-16: To be or not to be? (2000) (0)
- Molecular fingerprinting during endothelial cell differentiation (2000) (0)
- Consensus on the assessment of systemic sclerosis–associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment (2023) (0)
- POS0867 ALTERATION OF DUODENAL HISTOLOGY IN SYSTEMIC SCLEROSIS PATIENTS AFTER FECAL MICROBIOTA TRANSPLANTATION (2021) (0)
- Hemodynamic phenotypes in patients with systemic sclerosis screened for pulmonary hypertension (PH) – the impact of the new defintion of PH (2020) (0)
- Infectious and autoinflammatory modic type 1 changes have different pathomechanisms (2021) (0)
- FRI0491 Incidence and Predictors of Cutaneous Manifestations During the Early Course of Systemic Sclerosis – A 10 Year Longitudinal Study from the Eustar Database (2015) (0)
- Patient Assessment Chronic Illness Care (PACIC) and its associations with quality of life among Swiss patients with systemic sclerosis: a mixed methods study (2023) (0)
- SAT0008 INDIVIDUAL FUNCTIONS OF THE HISTONE-ACETYLTRANSFERASES CBP AND P300 IN REGULATING THE INFLAMMATORY RESPONSE BY AFFECTING HISTONE ACETYLATION AND MRNA STABILITY (2020) (0)
- OP0086 Long noncoding RNA H19X as a new therapeutic target for fibrosis (2017) (0)
- OP0040 Bucillamine and its metabolites induce synthesis of vegf dose dependently in systemic sclerosis fibroblasts via the nf-kb pathway (2001) (0)
- OP0085 ALTERED EXPRESSION OF NEUROTROPHINS AND THEIR RECEPTORS IN THE SKIN OF PATIENT WITH COMPLEX REGIONAL PAIN SYNDROME (CRPS) (2021) (0)
- Decline in Forced Vital Capacity Does Not Predict Further Progression of Interstitial Lung Disease in Systemic Sclerosis in the Following Period (2020) (0)
- SAT0001 FOSL-2 IS A REPRESSOR OF FOXP3 EXPRESSION DURING TREG DEVELOPMENT AND CONTROLS AUTOIMMUNITY (2019) (0)
- Title: European multicentre study validates ELF test as biomarker of fibrosis in systemic sclerosis (2018) (0)
- FRI0513 HISTONE-ACETYLTRANSFERASES CBP AND P300 REGULATE AUTOPHAGY AND PROTEASOMAL DEGRADATION IN SYNOVIAL FIBROBLASTS (2019) (0)
- Development of a composite index for clinical trials in early diffuse cutaneous systemic sclerosis - the combined response index in systemic sclerosis (2014) (0)
- SAT0312 MICRORNA-125B as a potential fibrotic and apoptotic regulator in systemic sclerosis (2017) (0)
- AB0669 The eular systemic sclerosis impact of disease (SCLEROID) score – a new patient-reported outcome measure for patients with systemic sclerosis – preliminary results from the ongoing validation study (2017) (0)
- Pain in idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and healthy controls: A report from the COVAD study (2022) (0)
- Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial (2022) (0)
- SAT0569 “IMAGES ARE MORE THAN PICTURES, THEY ARE DATA” [1] – EXPLORATION OF RADIOMICS ANALYSIS FOR SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (2020) (0)
- Sodium retention in partial portal vein ligated (PPVL) rats inmediated by metabolic liver function, not by peripheral arterialvasodilatation (2000) (0)
- Sarcoidosis - a multisystem disease. (2022) (0)
- Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads (2004) (0)
- Cardiac Remodeling in Systemic Sclerosis: TGF-beta/Fra2-Dependent Autophagy As a Novel Target for Heart Fibrosis (2017) (0)
- Purinergic signaling in systemic sclerosis. (2021) (0)
- AB0787 The eular systemic sclerosis impact of disease (SCLEROID) score – a new patient-reported outcome measure for patients with systemic sclerosis (2018) (0)
- Faculty Opinions recommendation of Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. (2009) (0)
- AB0724 Biomarkers Sensitive to Change in Patients with Systemic Sclerosis – a Systematic Review (2015) (0)
- SAT0380 Classification, categorisation and essential items for digital ulcer (DU) evaluation in systemic sclerosis (SSC): a desscipher/eustar survey (2017) (0)
- A66 ACTIVATION OF HEDGEHOG SIGNALLING PLAYS A CRUCIAL ROLE IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS (2010) (0)
- Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey (2022) (0)
- OP0015 Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis (2013) (0)
- OP-BRHE180353 502..510 (2019) (0)
- Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy (2015) (0)
- Is there a viral trigger for vascular manifestations in autoimmune diseases such as systemic sclerosis (2001) (0)
- Response to: ‘Correspondence on ‘Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial’’ by Bredemeier (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Oliver Distler?
Oliver Distler is affiliated with the following schools:
